---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-002033"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:45:57.343838+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma FY2023 net loss $18.9M; Berubicin DSMB OK, enrollment done, topline due H1 2025

## Summary
- Net loss $18.9M vs $15.3M in 2022; R&D expenses $14.1M (up from $9.3M) on Berubicin trial costs.
- Cash at Dec 31, 2023 only $0.5M; subsequent $4.0M public offering extends runway into late Q2 2024.
- Berubicin GBM study completed enrollment; DSMB recommended continue without modification after interim futility analysis.
- Topline data from potentially pivotal Berubicin trial expected in first half 2025.
- Appointed biotech commercialization leader Amy Mahery to Board of Directors.

## SEC filing metadata
- accession: 0001683168-24-002033
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824002033/0001683168-24-002033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824002033/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-002033
- JSON: https://secwatch.observer/filing/0001683168-24-002033.json
- Plain text: https://secwatch.observer/filing/0001683168-24-002033.txt

## Key facts
- Earnings Releases
  CNS Pharmaceuticals, Inc. reported the full year ended December 31, 2023 results: net income approximately $18.9 million.
  - Period: the full year ended December 31, 2023
  - Net income: approximately $18.9 million
  - Result: reported results
  source text: The net loss for the year ended December 31, 2023 was approximately $18.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824002033/0001683168-24-002033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.